scholarly journals Prognostic Autophagy-Related Genes of Gastric Cancer Patients on Chemotherapy

2020 ◽  
Author(s):  
xiaolong Liu ◽  
Zhen Ma ◽  
Lei Zhang ◽  
Yang Yu ◽  
Maswikiti Ewetse Paul ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chemotherapy Resistance ◽  
Risk Groups ◽  
Treatment Regimens ◽  
Chemotherapy Administration ◽  
Product Limit ◽  
The Subject ◽  
Gastric Cancer Patients ◽  
Gastric Malignancy ◽  
Proper Analysis

Abstract Background Chemotherapy resistance based on fluorouracil and cisplatin is one of the most encountered postoperative clinical problems in patients diagnosed with gastric cancer (GC), resulting in poor prognosis. Methods This study aimed to combine autophagy-related genes (ATGs) to investigate the susceptibility of victims with gastric malignancy to postoperative chemotherapy. Based on the TCGA database, gene expression data for GC patients undergoing and during chemotherapy were integrated and analyzed. Prognostic genes were screened based on univariate and various analysis regression models. Subjects were divided into high-risk and low-risk groups and analyzed by the median risk score approach. The product limit estimator method was used to evaluate the OS and DFS. The accuracy of the prediction was resolved by the subject curve analysis. In addition, proper analysis carrying out was done in our work for some detailed assessments. The differential expression of ATGs is mainly related to chemotherapy resistance. Results A total of 9 ATGs of chemotherapy administration outcomes in these suffers were screened. Based on GEO and TCGA databases, the model accurately predicted DFS and OS after chemotherapy administration. Conclusions This study established prognostic markers based on 9 genes, predicting that ATGs are related to chemotherapy susceptibility of GC patients, which can provide better individualized treatment regimens for clinical practice.

scholarly journals Prognostic Autophagy-Related Genes of Gastric Cancer Patients on Chemotherapy

2020 ◽  
Author(s):  
Xiaolong Liu ◽  
Zhen Ma ◽  
Yang Yu ◽  
Maswikiti Ewetse Paul ◽  
YanLin Ma ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chemotherapy Resistance ◽  
Risk Groups ◽  
Treatment Regimens ◽  
Chemotherapy Administration ◽  
Post Operation ◽  
Product Limit ◽  
The Subject ◽  
Gastric Cancer Patients ◽  
Gastric Malignancy

Abstract Background, Chemotherapy resistance based on the use of fluorouracil and cisplatin is one of the most encountered clinical problems resulting from post operation and gives rise to poor prognosis in patients diagnosed with gastric cancer (GC). Methods , this study aims to combine autophagy-related genes (ATGs) to provide an investigation of the susceptibility of victims with gastric malignancy to postoperative chemotherapy. Based on the TCGA database, gene expression data for GC patients undergoing and are using chemotherapy were integrated and analyzed. Prognostic genes were screened based on univariate and various analysis regression models. Subjects were divided into those with high and low-risk groups. This was analyzed by the utilization of the median risk score approach. The product limit estimator method had to be used to evaluate the OS and DFS. The accuracy of the prediction was resolved by the subject curve analysis. In addition, the carrying out of proper analysis was done in our work for some detailed assessments. The differential expression of ATGs is mainly related to chemotherapy resistance. Results, a total of 9 ATGs of chemotherapy administration outcomes in these suffers were screened. Based on GEO and TCGA databases, the model accurately predicted DFS and OS after chemotherapy administration. Conclusions, this study established prognostic markers based on 9 genes, which can predict ATGs related to chemotherapy susceptibility of GC patients, and provide better individualized treatment regimens for clinical practice.

scholarly journals Prognostic Autophagy-Related Genes of Gastric Cancer Patients on Chemotherapy

2021 ◽  
Author(s):  
xiaolong Liu ◽  
Zhen Ma ◽  
Lei Zhang ◽  
Yang Yu ◽  
Maswikiti Ewetse Paul ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Regression Models ◽  
Risk Group ◽  
Chemotherapy Resistance ◽  
Estimation Method ◽  
High Risk Group ◽  
Chemotherapy Administration ◽  
Clinical Complications ◽  
Product Limit ◽  
Gastric Cancer Patients

Abstract Background Gastric cancer(GC) treated with fluorouracil and cisplatin can cause chemotherapy resistance, which is one of the most common postoperative clinical complications and leads to in poor prognosis. Methods The purpose of this study is to investigate the susceptibility of patients with GC after postoperative chemotherapy based on autophagy-related genes (ATGs). Under the background of TCGA database, for patients with GC undergoing and during chemotherapy,gene expression data was integrated and analyzed. Prognostic genes were screened based on univariate and various analysis regression models. Subjects were divided into two groups: high-risk group and low-risk group. Univariate and various analytical regression models were used to screen for prognostic genes. Median risk score was used for analysis. OS and DFS were evaluated by the product limit estimation method. Subject curve analysis is used to determine the accuracy of the forecast. We also have performed appropriate analysis and conducted some detailed assessments in our work. The differential expression of ATGs was mainly associated with chemotherapy resistance.Results After chemotherapy administration, we have screened 9 ATGs outcomes in the subjects and DFS and OS were precisely predicted by the model of GEO and TCGA databases.Conclusions 9 genes were established as prognostic markers to predict the relationship between ATGs and GC chemotherapy susceptibility, suggesting a better individualized treatment in clinical practice.

Palliative prognostic tools for the terminally ill patients with gastric cancer.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 120-120 ◽  
Author(s):  
Beodeul Kang ◽  
Hye Jin Choi ◽  
Sun Young Rha
Keyword(s):  
Gastric Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Risk Group ◽  
Terminally Ill ◽  
Risk Groups ◽  
Low Risk ◽  
Intermediate Risk ◽  
Poor Risk ◽  
Gastric Cancer Patients

120 Background: Terminally ill patients with gastric cancer have specific gastrointestional symptoms and signs related with cancer progression. To estimate accurate survival expectancy of gastric cancer patients is important for timely decision making of their end of life issues. Methods: We reviewed the 276 patients with terminally ill gastric cancer who were treated at Yonsei Cancer Center between January 2007 and December 2011 and eventually were died. Retrospectively, we conducted the data of clinical signs, symptoms, and laboratory results at the time of cessation of the active treatment. Then, we established the palliative survival estimation model by stratification of risk group. Results: Median palliative survival time from the decision to stop further treatment to death was 42days. In the multivariate Cox regression analysis, 5 parameters were identified as prognostically significant factors: anorexia, dyspnea, hypoalbuminemia, elevated blood urea nitrogen, and elevated serum alkaline phosphatase. We scored each variables as 1-3 for symptom(1:asymptomatic, 2:symptomatic, 3:symptomatic requiring intervention) and 1-2 for lab results(1:normal, 2:abnormal) and summed up each scores. Using the total score, patients were divided into 3 risk groups: low-risk(5-7points), intermediate-risk(8-11points), and poor-risk patients(12point). As a result, median palliative survival for low-risk group(n=110) was 87.0±7.4days, intermediate-risk group(n=158) and poor-risk group(n=8) were 31.0±2.1days and 6.0±2.1days, respectively (p<0.0001). Conclusions: Using multivariate analysis and summation of each prognostic factor score, 3 risk groups were determined. After validation by prospective multicenter trial, this palliative survival time estimation tool will be helpful to inform the accurate survival for terminally ill gastric cancer patients.

scholarly journals Derived neutrophil by lymphocytes ratio is a misnomer, implication of derived leucocytes ratio in diagnosing gastric cancers

2018 ◽  
Vol 6 (1) ◽  
pp. 82
Author(s):  
Naveen P. G. ◽  
K. Veena L. Karanth
Keyword(s):  
Gastric Cancer ◽  
Complete Blood Count ◽  
Malignant Neoplasms ◽  
Surgical Removal ◽  
Mortality And Morbidity ◽  
Gastric Cancers ◽  
Upper Gi Endoscopy ◽  
Gastric Cancer Patients ◽  
Gastric Malignancy ◽  
Significant Mortality

Background: Gastric malignant neoplasms are well-known common malignant disease seen in routine clinical practice. In India incidence are comparatively low but accounts for significant mortality and morbidity. Gastric malignancy incidence adds significant numbers every year to cancer related deaths worldwide. And prognosis is not satisfactory in spite of medical innovations and technological advancements. Early diagnosis helps for successful surgical removal of gastric cancer and to achieve a curative resections. Present study objectives are to solve the paradox of misnomer derived neutrophil by lymphocyte ratio and to evaluate statistical differences of blood leucocyte parameters in patients with gastric malignancies as compared to control cases and its application as screening markers in diagnosing gastric cancers.Methods: Hundred cases of gastric malignancy and hundred controls-age, gender matched to cases without malignancy or infection were included. Both groups evaluated with routine complete blood count and upper GI endoscopy reports, Data regarding WBC counts, neutrophil counts, lymphocyte counts, monocytes, eosinophils and basophils were noted and Derived Leucocytes Ratio (DLR) were calculated and compared to look for statistical differences.Results: Hematological leucocyte parameters revealed statistical differences in gastric cancer patients in comparison to controls. Neutrophils were increased and lymphocytes decreased with elevated DLR levels.Conclusions: Leucocyte parameters like neutrophils and lymphocytes shows varying trends in gastric cancer and elevated derived leucocytes ratio can be utilized as a screening marker in Gastric cancers.

scholarly journals Prognostic factors in patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy: a cohort study

2021 ◽  
Author(s):  
Shoko Marshall ◽  
Takeru Wakatsuki ◽  
Daisuke Takahari ◽  
Tomohiro Matsushima ◽  
Naoki Ishizuka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Univariate Analysis ◽  
Risk Groups ◽  
Rank Test ◽  
Visceral Metastasis ◽  
Her2 Positive ◽  
Kaplan Meier ◽  
Laboratory Test Results ◽  
Gastric Cancer Patients

Abstract Purpose Prognostic factors for the survival of patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy remain controversial. The aim of this study was to identify the clinical factors that predict prognosis in patients with advanced HER2-positive gastric cancer. Methods We retrospectively reviewed the medical records of HER2-positive gastric cancer patients treated with trastuzumab-based chemotherapy at our institution. Clinical features and laboratory test results that considered prognostic factors were re-examined. Overall survival (OS) was estimated using the Kaplan-Meier method. Univariate analysis was performed with the log-rank test and multivariate analysis was performed using Cox’s proportional hazard regression model. Results A total of 133 patients with advanced HER2-positive gastric cancer were enrolled. The median OS in this cohort was 18.7 months. Four prognostic factors: visceral metastasis (lung or liver), levels of haemoglobin (Hb) (< 11.6 g/dL), lactate dehydrogenase (LDH) (> 222 mg/dL), and C-reactive protein (CRP) (> 0.14 mg/dl) were identified as independent prognostic factors. The patients were placed into three groups according to their number of prognostic factors. These included low (0,1), moderate (2,3), and high (4) risk factors. The OS was separated into three categories with a median OS of 32.0, 18.7 and 10.1 months respectively. Compared to the low-risk group, hazard ratios for the moderate- and high-risk groups were 1.75 and 3.49, respectively. Conclusion Visceral metastasis and abnormal Hb, LDH, and CRP levels were associated with unfavorable OS. These findings may be beneficial for the management of advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy.

scholarly journals Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: A Cohort study

2020 ◽  
Author(s):  
Shoko Marshall ◽  
Takeru Wakatsuki ◽  
Daisuke Takahari ◽  
Tomohiro Matsushima ◽  
Naoki Ishizuka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Univariate Analysis ◽  
Risk Groups ◽  
Rank Test ◽  
Test Results ◽  
Visceral Metastasis ◽  
Her2 Positive ◽  
Laboratory Test Results ◽  
Gastric Cancer Patients

Abstract Background: Prognostic factors for the survival of patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy remain controversial. The aim of this study was to reveal the clinical factors that predict prognosis in this patient population.Methods: We retrospectively reviewed the medical records of HER2-positive gastric cancer patients treated with trastuzumab-based chemotherapy in our institution. Clinical features and laboratory test results considered prognostic factors were re-examined. Overall survival (OS) was estimated using the Kaplan-Meier method, univariate analysis was performed with the log-rank test, and multivariate analysis using Cox’s proportional hazard regression model.Results: A total of 133 patients with advanced HER2-positive gastric cancer were enrolled. The median OS in this cohort was 18.7 months. Four prognostic factors: visceral metastasis (lung or liver), and levels of haemoglobin (Hb) (< 11.6 g/dL), lactate dehydrogenase (LDH) (> 222 mg/dL), and C-reactive protein (CRP) (> 0.14 mg/dl) were identified as independent prognostic factors. After classifying the patients in three groups according to their number of prognostic factors, namely low (0,1), moderate (2,3), and high (4) risk, OS curves were separated into three categories with median OS of 32.0, 18.7, and 10.1 months, respectively (p=0.00025). Compared to the low-risk group, hazard ratios for the moderate- and high-risk groups were 1.75 (95% CI: 1.05–2.93) and 3.49 (95% CI: 1.81–6.71), respectively.Conclusion: Visceral metastasis and abnormal Hb, LDH, and CRP test results were associated with unfavourable OS. These findings are helpful for the management of advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy.

scholarly journals The Diagnostic and Prognostic Value of BEN-Domain (BEND) Family Genes in Gastric Cancer

2022 ◽  
Author(s):  
Jiaxin Fan ◽  
Min Yang ◽  
Chaojie Liang ◽  
Chaowei Liang ◽  
Jiansheng Guo
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Risk Score ◽  
Prognostic Value ◽  
Risk Model ◽  
Malignant Tumors ◽  
Risk Groups ◽  
Risk Scores ◽  
Gastric Cancer Patients

Abstract BEND(BEN domain-containing protein)is a domain protein-coding gene, whose abnormal expression is related to the occurrence of malignant tumors. But studies on gastric cancer are rare. We attempted to investigate the role of BEND family genes in evaluating the prognosis of gastric cancer and guiding clinical treatment. We analyzed the BEND family genes expression, prognostic value, and drug sensitivity in pan-cancer, and the correlation between their expression and tumor microenvironment of gastric cancer, stemness index, immune subtypes, and clinicopathological characteristics were analyzed. We constructed a model using BEND3P1 and BEND6 to evaluate the prognosis of gastric cancer patients. Multivariate Cox proportional risk model analysis showed that risk score is an independent risk factor for gastric cancer patients. To assess the value of risk score for prognosis, patients were divided into high-risk and low-risk groups based on median risk scores, and survival analyses were performed. The results showed that the OS of patients with high-risk scores is significantly lower. We also constructed a nomogram to predict individual survival probability using the BEND risk score and clinical case characteristics. In conclusion, the BEND family genes can predict the prognosis and guide the treatment of gastric cancer patients.

Chemotherapy (CT) treatment patterns and neutropenia management in gastric cancer patients (pts) receiving myelosuppressive chemotherapy in Europe.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 128-128
Author(s):  
Ewa Kalinka-Warzocha ◽  
Javier Gallego Plazas ◽  
Laurent Mineur ◽  
Tomas Salek ◽  
Alain Hendlisz ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Risk Estimation ◽  
Primary Prophylaxis ◽  
Myelosuppressive Chemotherapy ◽  
Chemotherapy Administration ◽  
Treatment Naïve ◽  
Drug Regimens ◽  
The Mean ◽  
Gastric Cancer Patients

128 Background: Granulocyte-colony stimulating factor (G-CSF) primary prophylaxis (PP) is recommended for pts undergoing CT who are at overall high risk for febrile neutropenia (FN). No single CT regimen is recognized as standard in gastric cancer and few regimens are represented in G-CSF guidelines. We therefore evaluated neutropenia management in pts receiving CT for gastric cancer. Methods: This was a multicentre prospective observational study that enrolled pts sequentially from 11/2009 to 06/2011. Adult gastric cancer pts (any stage) with ≥3 cycles of myelosuppressive CT scheduled and an investigator-assessed overall FN risk ≥20% were eligible. The primary outcome was the proportion of pts who received PP G-CSF (G-CSF in days 1-7 of cycle 1). Secondary outcomes included FN incidence, chemotherapy administration, and G-CSF use. Posthoc analyses investigated the subgroup who received DCF, including modifications from standard DCF (Van Cutsem. JCO. 2006), and the G-CSF support given up to the first FN (G-CSF prophylaxis given per label in each cycle up to that in which FN occurred). Results: Of 209 pts enrolled, 199 were eligible and their data analyzed. The mean (±SD) age was 62 (±12) years, 76% were male, 17% were ECOG 2 and none ECOG 3-4; 47% were treatment naïve. Planned CT was palliative in 74% of pts; overall, 27 different backbone regimens were planned (10 triplet, 12 doublet, 5 single drug regimens). The most common regimen used was DCF (54 pts, 27%), predominantly given as modified DCF (41 pts). Despite being assessed as high risk for FN, G-CSF PP was administered to only 35% of pts overall (n=70; 54 pegfilgrastim, 16 daily G-CSF) and to 69% of pts who received DCF. FN occurred in 14 pts (10%), 9 of whom received DCF. A large majority of FN pts (12/14, 86%) had not received prophylactic G-CSF per label up to the first FN occurrence; furthermore, 86% of FN pts did not receive G-CSF prophylaxis in the cycle following the FN event. Conclusions: The variety of CT used, frequent modifications to standard CT, and presence of pt risk factors makes FN risk estimation difficult in gastric cancer. Improved risk assessment and appropriate targeting of G-CSF PP to high risk pts is needed.

Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role

2020 ◽  
Vol 27 (36) ◽  
pp. 6099-6111 ◽  
Author(s):  
Dimitrios Schizas ◽  
Aikaterini Mastoraki ◽  
Leon Naar ◽  
Diamantis I. Tsilimigras ◽  
Ioannis Katsaros ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gastric Cancer ◽  
Histone Deacetylases ◽  
Cell Cycle Control ◽  
Chemotherapy Resistance ◽  
Hdac Inhibitors ◽  
Metastatic Potential ◽  
Chemotherapy Drugs ◽  
Treatment Regimens ◽  
Synergistic Interactions

Chemotherapy resistance is a rising concern in Gastric Cancer (GC) and has led to the investigation of various cellular compounds. Α functional equilibrium of histone acetylation and deacetylation was discovered in all cells, regulated by Histone Acetyltransferases and Deacetylases (HDACs), controlling chromatin coiling status and changing gene expression appropriately. In accordance with recent research, this equilibrium can be dysregulated in cancer cells aiding in the process of carcinogenesis and tumor progression by altering histone and non-histone proteins affecting gene expression, cell cycle control, differentiation, and apoptosis in various malignancies. In addition, increased HDAC expression in GC cells has been associated with increased stage, tumor invasion, nodal metastases, increased distant metastatic potential, and decreased overall survival. HDAC inhibitors could be used as treatment regimens for GC patients and could develop important synergistic interactions with chemotherapy drugs. The aim of this article is to review the molecular identity and mechanism of action of HDAC inhibitors, as well as highlight their potential utility as anti-cancer agents in GC.

Sign in / Sign up

Export Citation Format

Share Document